Navigating Indirect Treatment Comparisons (ITC)
When head-to-head evidence is unavailable, conventional Indirect Treatment Comparisons (ITCs) can estimate the relative effects of competing treatments through a shared comparator. A Bucher adjusted indirect comparison combines treatment effects from two trials, or more generally studies1. The network meta-analysis (NMA) extends this principle across larger networks of treatments and studies, combining direct and indirect […]
Building External Control Arms (ECAs) to prove therapeutic value
RCTs not feasible? Think External Control Arms (ECAs)! The context: Beyond the Gold Standard Randomized Controlled Trials (RCTs) remain the gold standard to assess treatment effect. But they are sometimes impractical or even unfeasible, especially in rare diseases or severe oncology indications where assigning patients to a placebo or an outdated Standard of Care (SOC) […]
Projeter l’efficacité d’un traitement en vie réelle (VR) à partir d’une étude clinique randomisée (ECR) : une approche utilisant le suréchantillonnage
Event: 11ème Colloque Données de Santé en vie réelle 2019, AFCROs, Paris, France Authors: C. Esnault, M. Génin, S. Ekhtiari, A. Civet View Poster Introduction Bien qu’il n’y ait pas encore de consensus formel sur l’emploi des modèles statistiques pour estimer l’efficacité d’un traitement en VR, le besoin de son évaluation plus systématique est largement reconnu [1] […]
